dcgi gives emergency-use approval to covaxin, covishield vaccines
Published 3 years ago • 1.6K plays • Length 7:08Download video MP4
Download video MP3
Similar videos
-
8:49
bharat biotech's covaxin gets subject expert committee (sec) approval for emergency use
-
0:58
dcgi approves two vaccines for emergency use, who hails indian vaccines covishield, covaxin
-
2:31
covid-19 vaccine covishield, covaxin gets final approval from dcgi's expert panel | breaking news
-
6:59
india: dcgi approves serum & bharat biotech vaccines for emergency use | covaxin | covishield
-
1:52
covishield gets conditional approval from expert panel, waiting for dcgi's final approval
-
2:25
watch: pm modi receives second dose of covid vaccine; nurses share experience
-
2:17
india to roll out world's largest covid-19 vaccine campaign
-
3:29
top 8 vaccines for covid-19 | comparison
-
2:45
dcgi allows bharat biotech to vaccinate children above 12 during clinical trial mode
-
6:22
dcgi approves sii & bharat biotech's covid vaccines for restricted emergency use
-
1:35
india's drug regulator okays study on mixing covaxin and covishield
-
6:20
covaxin, covishield vaccines get emergency use approval; first covid-19 vaccines in india
-
14:37
dcgi gives nod to covishield & covaxin for restricted emergency use; clinical trials to continue
-
7:18
aiims director hails dcgi approval of 'india-made' covid vaccine
-
1:29
dcgi accepts expert committee report to allow covaxin jabs without clinical trial
-
3:12
final approval for covishield today; dcgi to take final call on the covid-19 vaccine
-
2:05
‘the covid-19 vaccines are 110% safe…’: dcgi v.g. somani
-
6:21
sii’s covishield gets nod from dcgi’s expert panel; covaxin yet to be given approval
-
0:43
covid vaccine should get usage approval after clearing all checks: congress
-
8:06
bharat biotech’s covid-19 vaccine for kids gets dcgi nod for emergency use
-
1:55
covid-19 vaccine: zydus cadila seeks emergency use approval of 'zycov-d' for 12 years and above
-
0:50
covaxin for kids: bharat biotech completes phase 2/3 trials, to submit data to dcgi next week